Genting strikes gold in TauRx
After years of researches and studies , finally TauRx released the full results and presentation of Phase 3 clinical studies of the flagship medicine named HMTM .
$GENTING(3182.MY$ is having a 20% stake in TauRx , in which it is currently not making profits as the principal product HMTM is still under development and yet to be commercialized.
With the data released from the clinical trials , it is likely that TauRx’s HMTM will get the approvals from authority of key market such as UK and US.
This is considered as “extra bonus” to Genting’s asset value , other than the current businesses. Maybank Investment Bank assigned a target price of RM 9.40 , if the product HMTM is approved and commercialized in the future
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
▶️ Chief Trainer @Sharix.my
▶️ grow portfolio from RM 10k to RM 1 mil in 5 yrs
▶️ follow my FB [Zeff的宏财伟略]
7829Followers
45Following
17KVisitors
Follow
SpyderCall : Might see a breakout of long-term resistance in this ticker. It is just below resistance now. Watch out for a rejection, though.
102932551 :
Wait for the harvest...